All In Biotech

Drug Trial Radar · NCT06833983

To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A

A Single-arm, Open-label, Multicenter Study Evaluating the Efficacy and Safety of GS1191-0445 Injection as a Single Dose in Chinese Subjects With Hemophilia A

Last checked: Nov 20, 2026Latest source record: Dec 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Mar 31, 2025

Primary completion

Nov 30, 2026

Study completion Nov 30, 2030

Sponsor

Lead sponsor
Gritgen Therapeutics Co., Ltd.Industry
Sponsor type
Industry
First posted
Feb 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a single-arm, open-label, multicenter study evaluating the efficacy and safety of GS1191-0445 injection as a single dose in Chinese subjects with hemophilia A. GS1191-0445 is an AAV8-based gene therapy vector designed to express B-domain deleted human factor VIII (FVIII) under the regulation of a human liver-specific promoter. Following a single intravenous administration, AAV8 targets hepatocytes and facilitates the specific expression and secretion of FVIII into the bloodstream.

Conditions

  • Hemophilia A

Interventions

  • GS1191-0445 injectionDrug

    A single intravenous administration of GS1191-0445 injection at a dose of 3E12 vg/kg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Bleeding Rate (ABR)Time frame: Weeks 3 to 52 after infusion

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Hospital

    Hefei, Anhui, China · Not yet recruiting

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • First Hospital of Lanzhou University

    Lanzhou, Gansu, China · Not yet recruiting

  • Nanfang Hospital Southern Medical University

    Guangzhou, Guangdong, China · Not yet recruiting

  • North China University of Science and Technology Affiliated Hospital

    Tangshan, Hebei, China · Not yet recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China · Not yet recruiting

  • Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, China · Not yet recruiting

  • Jiangxi Provincial People's Hospital

    Nanchang, Jiangxi, China · Not yet recruiting

  • Central Hospital Affiliated to Shandong First Medical University

    Jinan, Shandong, China · Recruiting

  • Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

    Tianjin, Tianjin Municipality, China · Recruiting

  • The second Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.